Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment

Abstract Pancreatic acinar cell carcinoma is a rare form (0.2–4.3%) of pancreatic neoplasm with unique clinical and molecular characteristics, which largely differ from pancreatic ductal adenocarcinoma. Pancreatic acinar cell carcinoma occurs more frequently in males and can occur in children. Serum lipase is elevated in 24–58% of patients with pancreatic acinar cell carcinoma. Pancreatic acinar cell carcinomas tend to be large at diagnosis (median tumour size: ~5 cm) and are frequently located in the pancreas head. Radiologically, pancreatic acinar cell carcinoma generally exhibits a solid appearance; however, necrosis, cystic changes and intratumoral haemorrhage can occur in larger lesions. Immunostaining is essential for the definitive diagnosis of pancreatic acinar cell carcinoma. Compared with pancreatic ductal adenocarcinoma, pancreatic acinar cell carcinoma has a more favourable prognosis. Although radical surgery is recommended for patients with pancreatic acinar cell carcinoma who do not have distant metastases, the recurrence rate is high. The effectiveness of adjuvant therapy for pancreatic acinar cell carcinoma is unclear. The response to FOLFIRINOX is generally favourable, and some patients achieve a complete response. Pancreatic acinar cell carcinoma has a different genomic profile compared with pancreatic ductal adenocarcinoma. Although genomic analyses have shown that pancreatic acinar cell carcinoma rarely has KRAS, TP53 and CDKN2A mutations, it has a higher prevalence of homologous recombination-related genes, including BRCA1/2 and ATM, than pancreatic ductal adenocarcinoma, suggesting high sensitivity to platinum-containing regimens and PARP inhibitors. Targeted therapies for genomic alternations are beneficial. Therefore, genetic testing is important for patients with pancreatic acinar cell carcinoma to choose the optimal therapeutic strategy.

[1]  Naomi Uchiyama,et al.  Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary–pancreatic cancers , 2023, Journal of Gastroenterology.

[2]  M. Hogg,et al.  Adult Pancreatoblastoma: a Rare Pancreatic Tumor. , 2023, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.

[3]  Tsutomu Sato,et al.  A resected case of acinar cell carcinoma of the pancreas with liver metastasis following chemotherapy using modified FOLFIRINOX , 2023, Surgical Case Reports.

[4]  M. Ladanyi,et al.  Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Sasahira,et al.  Outcomes of lung oligometastasis in pancreatic cancer. , 2023, Japanese journal of clinical oncology.

[6]  M. Bali,et al.  Rare Solid Pancreatic Lesions on Cross-Sectional Imaging , 2023, Diagnostics.

[7]  Dakeun Lee,et al.  Simultaneous establishment of pancreatic cancer organoid and cancer‐associated fibroblast using a single‐pass endoscopic ultrasound‐guided fine‐needle biopsy specimen , 2023, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[8]  D. Jain,et al.  Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma , 2023, Diagnostic cytopathology.

[9]  I. Tirosh,et al.  Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting , 2023, Cancer discovery.

[10]  P. Kornprat,et al.  Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas - A multicentric European study on radically resected patients. , 2023, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[11]  Rachel B. Keller,et al.  Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness , 2023, JCO precision oncology.

[12]  K. Takaori,et al.  Mixed acinar-neuroendocrine carcinoma of the pancreas with positive for microsatellite instability: a case report and review of the literature , 2023, Surgical Case Reports.

[13]  G. Sauter,et al.  CELA3B immunostaining is a highly specific marker for acinar cell carcinoma of the pancreas , 2023, PloS one.

[14]  K. Takami,et al.  Outcomes of surgical resection for pulmonary metastasis from pancreatic cancer , 2023, Surgery Today.

[15]  W. Korn,et al.  Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC)Unveils New Actionable Genomic Aberrations in PACC. , 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  R. Schulick,et al.  Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. , 2023, Surgery.

[17]  Y. Matsuno,et al.  Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers , 2023, Cancer science.

[18]  G. Mazzarella,et al.  Solid pseudopapillary tumor of the pancreas: A systematic review of clinical, surgical and oncological characteristics of 1384 patients underwent pancreatic surgery. , 2023, Hepatobiliary & pancreatic diseases international : HBPD INT.

[19]  H. Seno,et al.  A case of unresectable ectopic acinar cell carcinoma developed in the portal vein in complete response to FOLFIRINOX therapy , 2023, Clinical Journal of Gastroenterology.

[20]  M. Moriguchi,et al.  Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan , 2023, Journal of Gastroenterology.

[21]  R. Yamada,et al.  Pancreatic Mixed Acinar-neuroendocrine-ductal Carcinoma: A Case Report and Literature Review , 2023, Internal medicine.

[22]  R. Pommier,et al.  Referral and treatment patterns in pancreatic acinar cell carcinoma: A regional population-level analysis. , 2023, American journal of surgery.

[23]  M. Budzik,et al.  Rare Non-Neuroendocrine Pancreatic Tumours , 2023, Cancers.

[24]  G. Prager,et al.  Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. , 2023, European journal of cancer.

[25]  T. Okusaka,et al.  Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreaticobiliary Cancer Aiming for a Comprehensive Genome Profile , 2023, Diagnostics.

[26]  P. Philip,et al.  Neoadjuvant therapy for pancreatic cancer , 2023, Nature Reviews Clinical Oncology.

[27]  T. Ohtsuka,et al.  Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis , 2023, International Journal of Clinical Oncology.

[28]  Yang Zhang,et al.  Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma? , 2023, Journal of cancer metastasis and treatment.

[29]  N. Hiraoka,et al.  Novel Insights Into Immunohistochemical Analysis For Acinar Cell Neoplasm of The Pancreas , 2023, The American journal of surgical pathology.

[30]  N. Sugimoto,et al.  Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice , 2023, Cancers.

[31]  G. Gores,et al.  Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States , 2023, Cancers.

[32]  E. Chiorean,et al.  The role of molecular testing in pancreatic cancer , 2023, Therapeutic advances in gastroenterology.

[33]  J. Neoptolemos,et al.  Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. , 2022, The lancet. Gastroenterology & hepatology.

[34]  H. Trottier,et al.  Endoscopic Ultrasound Guided Fine Needle Aspiration versus Endoscopic Ultrasound Guided Fine Needle Biopsy for Pancreatic Cancer Diagnosis: A Systematic Review and Meta-Analysis , 2022, Diagnostics.

[35]  M. Fukayama,et al.  Derivation of pancreatic acinar cell carcinoma cell line HS‐1 as a patient‐derived tumor organoid , 2022, Cancer science.

[36]  Dheeraj R. Gopireddy,et al.  Pancreatic acinar cell carcinoma: A comprehensive review , 2022, World journal of gastroenterology.

[37]  Yu Liu,et al.  Differentiation between solid pseudopapillary tumor and acinar cell carcinoma of the pancreas based on computed-tomography features. , 2022, Asian journal of surgery.

[38]  K. Nagai,et al.  Exceptional Response of Pancreatic Acinar Cell Carcinoma and Bile Duct Cancer to Platinum-Based Chemotherapy in a Family With a Germline BRCA2 Variant. , 2022, Pancreas.

[39]  T. Okusaka,et al.  The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry , 2022, Journal of Gastroenterology.

[40]  S. Yagi,et al.  Pancreatic acinar cell carcinoma projected from the ampulla of Vater with extensive intraductal tumour growth. , 2022, The American journal of gastroenterology.

[41]  S. Yachida,et al.  Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. , 2022, Japanese journal of clinical oncology.

[42]  Joon-Oh Park,et al.  Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Unno,et al.  Pancreatic mixed acinar–neuroendocrine carcinoma in a patient with a germline BRCA2 mutation: a case report , 2022, Clinical Journal of Gastroenterology.

[44]  K. Deng,et al.  Imaging and Clinicopathological Features of Acinar Cell Carcinoma , 2022, Frontiers in Oncology.

[45]  Shota Yamamoto,et al.  Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report , 2022, Cancer reports.

[46]  E. Sokol,et al.  The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. , 2022, Journal of the National Cancer Institute.

[47]  R. Ashida,et al.  Endoscopic ultrasound‐guided tissue acquisition for pancreatic ductal adenocarcinoma in the era of precision medicine , 2022, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[48]  N. Sasahira,et al.  Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study , 2022, Annals of Surgical Oncology.

[49]  S. Yamada,et al.  Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01) , 2022, Annals of surgery.

[50]  M. Papotti,et al.  Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms , 2022, Endocrine Pathology.

[51]  Kazuhiro Yoshida,et al.  Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis , 2022, Journal of hepato-biliary-pancreatic sciences.

[52]  M. Takenaka,et al.  Comparison of 22G Standard and Franseen Needles in Endoscopic Ultrasound-Guided Tissue Acquisition for Diagnosing Solid Pancreatic Lesions: A Multicenter Randomized Controlled Trial. , 2022, Gastrointestinal endoscopy.

[53]  R. Higuchi,et al.  A case of pathologically complete response after preoperative chemotherapy in a pancreatic acinar cell carcinoma patient with portal vein tumor thrombosis , 2022, Clinical Journal of Gastroenterology.

[54]  S. Maithel,et al.  Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma , 2022, Journal of surgical oncology.

[55]  K. Ohkawa,et al.  Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer , 2022, Endoscopy International Open.

[56]  D. Melisi,et al.  Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion , 2022, JCO precision oncology.

[57]  T. Keck,et al.  Survival Outcome and Prognostic Factors for Pancreatic Acinar Cell Carcinoma: Retrospective Analysis from the German Cancer Registry Group , 2021, Cancers.

[58]  Jin‐Young Jang,et al.  Clinical Characteristics of Resected Acinar Cell Carcinoma of the Pancreas: A Korean Multi-Institutional Study , 2021, Cancers.

[59]  T. Teshima,et al.  The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer , 2021, Cancers.

[60]  A. Omiyale Adult pancreatoblastoma: Current concepts in pathology , 2021, World journal of gastroenterology.

[61]  G. Sauter,et al.  Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas , 2021, The American journal of surgical pathology.

[62]  A. Biankin,et al.  Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  H. Imaoka,et al.  Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis , 2021, Diagnostics.

[64]  C. Weldon,et al.  Pancreatoblastoma in children: EXPeRT/PARTNER diagnostic and therapeutic recommendations , 2021, Pediatric blood & cancer.

[65]  K. Ohkawa,et al.  Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer , 2021, JGH open : an open access journal of gastroenterology and hepatology.

[66]  Jeffrey W. Clark,et al.  Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[67]  K. Nathanson,et al.  Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2 , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  A. Nakano,et al.  Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study , 2021, BMC Surgery.

[69]  Zhengjia Chen,et al.  Survival Outcomes of Acinar Cell Pancreatic Cancer , 2021, Pancreas.

[70]  M. Unno,et al.  Acinar Cell Carcinoma with Morphological Change in One Month , 2021, Internal medicine.

[71]  D. Jäger,et al.  Metastatic Acinar Cell Carcinoma of the Pancreas , 2021, Pancreas.

[72]  Ling Zhang,et al.  Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison to pancreatic ductal adenocarcinoma. , 2021, Surgical oncology.

[73]  Fenghua Wang,et al.  Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature , 2021, Clinical Medicine Insights. Oncology.

[74]  R. Berger,et al.  Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. , 2021, Gastroenterology.

[75]  E. Petricoin,et al.  Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[76]  D. Cao,et al.  Efficacy of chemotherapy combined with toripalimab in PD-L1–positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report , 2020, Tumori.

[77]  M. Li,et al.  The contemporary trend in worsening prognosis of pancreatic acinar cell carcinoma: A population-based study , 2020, PloS one.

[78]  H. Friess,et al.  Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. , 2020, The lancet. Gastroenterology & hepatology.

[79]  J. Furuse,et al.  Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma , 2020, Pancreas.

[80]  E. Stelow,et al.  The cytologic and immunohistochemical findings of pancreatic mixed acinar‐endocrine carcinoma , 2020, Diagnostic cytopathology.

[81]  W. Lou,et al.  Clinical Analysis of Acinar Cell Carcinoma of the Pancreas: A Single-Center Experience of 45 Consecutive Cases , 2020, Cancer control : journal of the Moffitt Cancer Center.

[82]  S. Fröhling,et al.  Successful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma , 2020, Cold Spring Harbor molecular case studies.

[83]  P. Kurtin,et al.  CPA1 and REG1a as New Markers for Pancreatic Acinar Cell Carcinoma. , 2020, Human Pathology.

[84]  S. Ramkissoon,et al.  Pediatric BRAF (V600E)-Mutated Pancreatic Acinar Cell Carcinoma With Complete and Durable Response to Dabrafenib and Trametinib. , 2020, JCO precision oncology.

[85]  Y. Kimura,et al.  Rare case of acinar cell carcinoma with multiple lesions in the pancreas , 2020, JGH open : an open access journal of gastroenterology and hepatology.

[86]  T. Fishbein,et al.  Robot-assisted combined pancreatectomy/hepatectomy for metastatic pancreatic acinar cell carcinoma: case report and review of the literature , 2020, Clinical Journal of Gastroenterology.

[87]  L. Shen,et al.  Patients With Acinar Cell Carcinoma of the Pancreas After 2005 , 2020, Pancreas.

[88]  N. Ohike,et al.  A case of pancreatic mixed acinar–neuroendocrine carcinoma successfully diagnosed with endoscopic ultrasound-guided fine needle aspiration , 2020, Clinical Journal of Gastroenterology.

[89]  N. Schultz,et al.  Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection , 2020, Clinical Cancer Research.

[90]  R. Hruban,et al.  Acinar cell carcinoma of the pancreas: a clinicopathologic and cytomorphologic review. , 2020, Journal of the American Society of Cytopathology.

[91]  G. Lahat,et al.  Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer , 2020, Annals of Surgical Oncology.

[92]  E. Petricoin,et al.  Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. , 2020, The Lancet. Oncology.

[93]  P. Kuo,et al.  Clinically resectable acinar cell carcinoma of the pancreas: Is there a benefit to adjuvant systemic therapy? , 2020, American journal of surgery.

[94]  D. Park,et al.  Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours. , 2020, Pathology.

[95]  F. Motoi,et al.  Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. , 2020, Japanese journal of clinical oncology.

[96]  A. Chen,et al.  Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  L. Wood,et al.  Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features. , 2019, Archives of pathology & laboratory medicine.

[98]  S. Katagiri,et al.  Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report. , 2019, Japanese journal of clinical oncology.

[99]  Kat S. Moore,et al.  Pancreatic cancer organoids recapitulate disease and allow personalized drug screening , 2019, Proceedings of the National Academy of Sciences.

[100]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[101]  K. Landa,et al.  Underutilization of surgical resection in patients with pancreatic acinar cell carcinoma. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[102]  I. Nagtegaal,et al.  Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review , 2019, Cancer biology & therapy.

[103]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[104]  D. Cao,et al.  Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib , 2018, Medicine.

[105]  Sheng-ping Li,et al.  Nomogram to Predict Cancer-Specific Survival in Patients with Pancreatic Acinar Cell Carcinoma: A Competing Risk Analysis , 2018, Journal of Cancer.

[106]  S. Cingarlini,et al.  Imaging presentation of pancreatic neuroendocrine neoplasms , 2018, Insights into Imaging.

[107]  Robert E Denroche,et al.  Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. , 2018, Cancer discovery.

[108]  E. Fishman,et al.  Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance , 2018, Abdominal Radiology.

[109]  D. V. Von Hoff,et al.  Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors , 2017, World journal of gastroenterology.

[110]  H. Ohira,et al.  Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma , 2017, Clinical Journal of Gastroenterology.

[111]  M. Matsuda,et al.  Pancreatic acinar cell carcinoma with extensive tumor embolism at the trunk of portal vein and pancreatic intraductal infiltration , 2017, Clinical Journal of Gastroenterology.

[112]  M. Omata,et al.  Genetic basis of a common tumor origin in the development of pancreatic mixed acinar-neuroendocrine-ductal carcinoma: A case report , 2017, Oncology letters.

[113]  D. Tuveson,et al.  Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. , 2017, Gastrointestinal endoscopy.

[114]  Tae Won Kim,et al.  Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[115]  D. Coppola,et al.  Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas. , 2016, Cancer control : journal of the Moffitt Cancer Center.

[116]  J. Werner,et al.  Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma , 2016, Journal of Cancer Research and Clinical Oncology.

[117]  S. Muthuswamy Abstract PR01: Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids , 2016 .

[118]  N. Sata,et al.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) , 2016, The Lancet.

[119]  Sinan Wang,et al.  Acinar cell carcinoma: a report of 19 cases with a brief review of the literature , 2016, World Journal of Surgical Oncology.

[120]  C. Yeo,et al.  Neoadjuvant Chemotherapy and Appleby Procedure for Pancreatic Acinar Cell Carcinoma: A Case Report , 2016, Case reports in pancreatic cancer.

[121]  Jun Dong,et al.  Clinical features and CT/MRI findings of pancreatic acinar cell carcinoma. , 2015, International journal of clinical and experimental medicine.

[122]  F. Sessa,et al.  Acinar Cell Carcinoma of the Pancreas: Overview of Clinicopathologic Features and Insights into the Molecular Pathology , 2015, Front. Med..

[123]  Masakazu Yamamoto,et al.  Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas , 2015, Scientific Reports.

[124]  M. Spector,et al.  Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.

[125]  R. Gershoni-baruch,et al.  Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers , 2014, British Journal of Cancer.

[126]  J. Herman,et al.  Whole‐exome sequencing of pancreatic neoplasms with acinar differentiation , 2014, The Journal of pathology.

[127]  P. Bhosale,et al.  CT imaging features of acinar cell carcinoma and its hepatic metastases , 2013, Abdominal Imaging.

[128]  R. Hruban,et al.  Acinar Cell Carcinoma of the Pancreas: Clinical and Cytomorphologic Characteristics , 2013, Korean journal of pathology.

[129]  Y. Yatabe,et al.  BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens , 2013, Pathology international.

[130]  J. Cameron,et al.  Acinar cell carcinoma of the pancreas: computed tomography features—a study of 15 patients , 2013, Abdominal Imaging.

[131]  A. Vanoli,et al.  Clinicopathologic Study of 62 Acinar Cell Carcinomas of the Pancreas: Insights Into the Morphology and Immunophenotype and Search for Prognostic Markers , 2012, The American journal of surgical pathology.

[132]  H. Imamura,et al.  Acinar cell carcinoma of the pancreas: a possible role of S-1 as chemotherapy for acinar cell carcinoma. A case report. , 2012, JOP : Journal of the pancreas.

[133]  M. Lowery,et al.  Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. , 2011, The oncologist.

[134]  M. Büchler,et al.  Acinar cell carcinoma of the pancreas: is resection justified even in limited metastatic disease? , 2011, American journal of surgery.

[135]  J. Tseng,et al.  CT and MRI features of acinar cell carcinoma of the pancreas with pathological correlations. , 2010, Clinical radiology.

[136]  Cynthia S. Johnson,et al.  Pancreatic Acinar Cell Carcinoma: A Multi-institutional Study , 2009, Journal of Gastrointestinal Surgery.

[137]  K. Lillemoe,et al.  Acinar Cell Carcinoma of the Pancreas in the United States: Prognostic Factors and Comparison to Ductal Adenocarcinoma , 2008, Journal of Gastrointestinal Surgery.

[138]  W. Nealon,et al.  672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. , 2008, Surgery.

[139]  Masao Tanaka,et al.  Acinar Cell Carcinoma of the Pancreas: Clinical Analysis of 115 Patients From Pancreatic Cancer Registry of Japan Pancreas Society , 2007, Pancreas.

[140]  O. Basturk,et al.  Intraductal and Papillary Variants of Acinar Cell Carcinomas: A New Addition to the Challenging Differential Diagnosis of Intraductal Neoplasms , 2007, The American journal of surgical pathology.

[141]  D. Klimstra Nonductal neoplasms of the pancreas , 2007, Modern Pathology.

[142]  S. Silverman,et al.  CT and MRI features of pure acinar cell carcinoma of the pancreas in adults. , 2005, AJR. American journal of roentgenology.

[143]  F. Motoi,et al.  Pancreatic Cancer Registry in Japan: 20 Years of Experience , 2004, Pancreas.

[144]  Cheng‐Yen Chang,et al.  Acinar Cell Carcinoma of the Pancreas: Clinical and Computed Tomography Manifestations , 2004, Journal of computer assisted tomography.

[145]  Jong Hoon Kim,et al.  Locally advanced acinar cell carcinoma of the pancreas successfully treated by capecitabine and concurrent radiotherapy: report of two cases. , 2003, Pancreas.

[146]  M. Gonen,et al.  Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  C. Compton,et al.  Prevalence and Prognostic Significance of Acinar Cell Differentiation in Pancreatic Endocrine Tumors , 2002, The American journal of surgical pathology.

[148]  S. D. Lee,et al.  Concurrent chemoradiation is effective in the treatment of alpha-fetoprotein-producing acinar cell carcinoma of the pancreas: report of a case. , 2001, Pancreas.

[149]  N. Lemoine,et al.  Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. , 1993, The American journal of pathology.

[150]  D. Klimstra,et al.  Acinar Cell Carcinoma of the Pancreas: A Clinicopathologic Study of 28 Cases , 1992, The American journal of surgical pathology.

[151]  J. C. Robertson,et al.  Syndrome associated with pancreatic acinar cell carcinoma. , 1970, British medical journal.

[152]  H. Macmahon,et al.  Acinar cell carcinoma of the pancreas with subcutaneous fat necrosis. , 1965, Gastroenterology.

[153]  L. Koniaris,et al.  Malignant pancreatic tumors: incidence and outcome in 58 pediatric patients. , 2009, Journal of pediatric surgery.

[154]  R. Grützmann,et al.  World Journal of Surgical Oncology Open Access Curative Resection of a Primarily Unresectable Acinar Cell Carcinoma of the Pancreas after Chemotherapy , 2022 .

[155]  M. Kako,et al.  World Journal of Gastroenterology , 2022 .